Product Description
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25034361/)
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Bosnia | Brazil | Canada | Croatia | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: Atrial Fibrillation | Embolism | Embolism and Thrombosis | Thrombosis | Ischemic Stroke | Stroke | Pulmonary Embolism
Known Adverse Events: Anemia | Injuries/wounds Unspecified
Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Brazil, Bulgaria, Canada, Chile, Croatia, Czech Republic, Denmark, El Salvador, France, Germany, Guatemala, Hungary, India, Israel, Japan, Kenya, Korea, Lebanon, Malaysia, Netherlands, Norway, Panama, Portugal, Romania, Russia, Serbia, Singapore, Slovenia, Spain, Taiwan, Thailand, Turkey, Ukraine, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Coronary Artery Disease|Embolism and Thrombosis|Hypertension, Pulmonary|Pulmonary Embolism|Venous Thromboembolism|Venous Thrombosis
Phase 2: Atrial Fibrillation|Embolism|Mitral Valve Stenosis|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Edoxaban | P3 |
Recruiting |
Coronary Artery Disease |
2024-12-30 |
|
| ERTEMIS | P2 |
Recruiting |
Stroke|Mitral Valve Stenosis|Embolism|Atrial Fibrillation |
2024-05-20 |
|
| KABUKI | P3 |
Completed |
Hypertension, Pulmonary |
2023-03-30 |
|
| EdoxCKD | P2 |
Active, not recruiting |
Atrial Fibrillation |
2022-09-03 |